A Phase 3 Randomized Double-Blind Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Cardiomyopathy

Brief description of study

Eidos Therapeutics, Inc. (the Sponsor) is conducting a research study to see if an investigational study medicine named AG10, will help in the treatment of a rare disease called Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM) that occurs when a protein, called transthyretin, is accumulated in the heart. This research study will check how safe and effective AG10 is in people with that disease. Investigational means the AG10 has not been approved by the US Food and Drug Administration (FDA).


Clinical Study Identifier: s18-02060
ClinicalTrials.gov Identifier: NCT03860935
Principal Investigator: Alex Reyentovich
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.